Maravai LifeSciences
MRVI
204 hedge funds and large institutions have $1.35B invested in Maravai LifeSciences in 2023 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 97 increasing their positions, 55 reducing their positions, and 46 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
76% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 55
75% more call options, than puts
Call options by funds: $3.12M | Put options by funds: $1.78M
6.08% more ownership
Funds ownership: 96.18% → 102.27% (+6.1%)
8% less funds holding
Funds holding: 221 → 204 (-17)
15% less capital invested
Capital invested by funds: $1.58B → $1.35B (-$231M)
35% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 46
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$44.4M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$38.8M |
| 3 |
1WCM
12 West Capital Management
New York
|
+$34.1M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
+$23.8M |
| 5 |
Holocene Advisors
New York
|
+$23.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$33M |
| 2 |
Citigroup
New York
|
-$23.7M |
| 3 |
Two Sigma Investments
New York
|
-$20M |
| 4 |
RI
RTW Investments
New York
|
-$19.1M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$16.3M |
MRVI Hedge Fund Activity: Q3 2023 in Review
204 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q3 2023, worth a combined $1.35B — down 15% from $1.58B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of MRVI and 30 opened new positions — a net loss of 16 holders — while 55 trimmed existing stakes and 97 added.
The largest buyer was Millennium Management, adding an estimated $44.4M. The largest seller was Massachusetts Financial Services, cutting an estimated $33M.
- 204 institutional investors held Maravai LifeSciences (MRVI) as of Q3 2023, down from 221 in Q2 2023.
- Funds reported $1.35B of Maravai LifeSciences stock for Q3 2023, down 15% quarter-over-quarter.
- 30 funds opened new Maravai LifeSciences positions in Q3 2023 and 46 closed out, a net change of -16 holders.
- The largest Maravai LifeSciences buyer in Q3 2023 was Millennium Management, an estimated $44.4M added.
- The largest Maravai LifeSciences seller in Q3 2023 was Massachusetts Financial Services, an estimated $33M sold.
Based on aggregated 13F filings for Q3 2023.